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Add-on and withdrawal effect of pravastatin on proteinuria in
hypertensive patients treated with AT1 receptor blockers.
Background. Although angiotensin receptor antagonists and
3-hydroxy-3-methylgultaryl coenzyme A (HMG-CoA) reduc-
tase inhibitors (statins) have been shown to attenuate pro-
teinuria individually, it remains unclear whether proteinuria
may be additionally improved by statin therapy in well-
controlled hypertensive patients treated with angiotensin re-
ceptor antagonists–based regimen and whether withdrawal of
chronic statin treatment may abrogate this beneficial effect in
normolipidemic patients.
Methods. A total of consecutive 82 proteinuric patients
treated with antihypertensive agents, including losartan, were
randomized 10 mg of pravastatin or placebo with a 6-month
treatment. After completing 6 months of drug treatment, the
pravastatin-treated patients were randomly assigned to con-
tinue (N = 19) or withdraw (N = 17) pravastatin for a further
6 months.
Results. Subjects treated with pravastatin had significant fur-
ther improvement of proteinuria at 6 months compared with
placebo group (559 ± 251 mg/24 hours vs. 1262 ± 557 mg/24
hours) (P < 0.0001). Of 17 patients assigned to withdraw pravas-
tatin, proteinuria returned to the pretreatment levels and was
significantly higher than those who continued treatment. Mul-
tivariate analysis revealed that proteinuric improvement was
significantly correlated with the continuous statin use. Urinary
excretion of endothelin-1 (ET-1) is decreased in pravastatin-
treated patients, but withdrawal of statin resulted in 27% up-
regulation. The linear regression models in the initial statin-
treated group showed that changes in urinary ET-1 correlated
with urinary protein excretion (r = 0.83, P < 0.0001).
Conclusion. We conclude that pravastatin administration is
associated with improved proteinuria probably by inhibiting
urine ET-1 levels in patients with losartan-based treatment.
However, statin withdrawal abrogates this beneficial effect in
patients initially responsive to this therapy.
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Epidemiologic studies have shown that urinary pro-
tein excretion is a strong and independent predictor of
nephropathy [1]. Ruilope et al [2] have shown the oc-
currence of overt proteinuria in 17.5% of patients with
chronic and well-controlled hypertension. Therefore, al-
though tight blood pressure control is known to be a
crucial factor in preventing progression of renal disease,
other factors are undoubtedly involved. Angiotensin-
converting enzyme (ACE) inhibitors [3] and angiotensin
II receptor blockers (ARBs) [4] are established therapeu-
tic option for treating proteinuria. However, these drugs
slow, but may not halt, the proteinuric progression and
may be not effective to the same degree in all patients [5].
The basis for persistent proteinuria despite ARB treat-
ment may be caused by the lack of effective attenuated
expression of endothelin-1 (ET-1) at unstimualted con-
ditions [6]. We [7] have previously demonstrated that
pravastatin [an 3-hydroxy-3-methylgultaryl coenzyme A
(HMG-CoA) reductase inhibitor] provides a beneficial
effect in improving proteinuria mediated by inhibiting re-
nal ET-1 synthesis. The usefulness of ARBs and statins for
proteinuria has been demonstrated individually. Whether
their coadministration may be superior to ARBs alone in
reducing proteinuria in normolipidemic patients and the
pharmacologic mechanisms underlying the benefit of the
combination therapy remain poorly understood.
Despite the clinical effect of statins on proteinuria,
duration of statins is not established and the effects of
withdrawing statin treatment remain unknown. Experi-
mental studies have shown that the withdrawal of statin
therapy leads to a profound rebound phenomenon with
increased proinflammatory genes [8] and reduced nitric
oxide [9]. Clinical studies have suggested that withdrawal
of statin therapy might be associated with worsening car-
diac events such as death and myocardial infarction [10],
independent of lipid-lowering, which may be of high rel-
evance for the clinical use of these drugs. These evi-
dences imply that most subjects should be retested from
statin withdrawal. Thus, the aims of the study were (1) to
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Fig. 1. Flow diagram of the study. For exclu-
sion criteria, see text.
evaluate whether combination treatment with a statin
may be superior to ARBs alone in improving protein-
uria; (2) to assess whether withdrawal of chronic statin
treatment may abrogate this beneficial effect; and (3) to
test whether the effects were related to modulation of
renal ET-1 synthesis.
METHODS
Patients
This study was conducted prospectively in a paral-
lel, double-blind, randomized, and controlled manner.
The design of pravastatin use was described previously
[7]. Eligible patients were required to have stable well-
controlled hypertension with a seated diastolic blood
pressure of 90 mm Hg or less and systolic blood pres-
sure of 140 mm Hg at a 3-month screening period.
Because standard therapy for patients with proteinuria
includes ARBs [6], patients were eligible for enrollment
if hypertension was treated with losartan-based regimen
for at least 3 months. To minimize selection bias, we con-
secutively enrolled patients. Proteinuria was defined as
urinary protein excretion exceeding 300 mg/24 hours in
two consecutive 24-hour urine samples without evidence
of urinary-tract infection or overt heart failure. Patients
were excluded from the study if they had diabetes mel-
litus, secondary hypertension, renal disease (serum cre-
atinine concentration ≥1.5 mg/dL or 133 lmol/L), pro-
teinuria of 3 g/day or more, hyperlipidemia (plasma to-
tal cholesterol level ≥240 mg/dL), or treatment with
corticosteroids, or nonsteroidal anti-inflammatory drugs
(NSAIDs). Before they were enrolled in this study, no
patients had ever received cholesterol-lowering agents.
Dosages of all concomitant medications were kept con-
stant throughout the study, when feasible. Apart from the
antihypertensive drugs, none of the patients were taking
any other drugs. No specific counseling about diet was
offered during the study period. Each patient received a
randomized code number, according to which the study
assistant supplied the study drug. Special drug packaging
was used to maintain blindness of treatment. A sealed
envelope, with information on the treatment allocated,
was kept in the clinical file of each patient. The study
was conducted in accordance with good clinical practices.
All patients were assessed at the outpatient clinic at four
weekly intervals. Compliance was defined as (number of
tablets dispensed-number of tablets returned at the next
visit)/(number of days on drug-1). A total of consecu-
tive 82 proteinuric patients were randomized 10 mg of
pravastatin (once daily) or placebo, in addition to their
existing losartan-based antihypertensive therapy with a
6-month treatment. After completing 6 months of
double-blind study drug treatment, the pravastatin-
treated patients were randomly assigned to continue (N =
19) or withdraw (N = 17) pravastatin for an additional
6 months (Fig. 1). The protocol was approved by an
ethical committee, and patients were required to sign
an informed consent form before undergoing screening
procedures.
According to the Third Report of the National Choles-
terol Education Program Adult Treatment Panel III cri-
teria [11], a metabolic syndrome was diagnosed when
hypertension coexisted with at least two of the follow-
ing four abnormalities: obesity, low hig-density lipopro-
tein (HDL), high fasting glucose ≥110 mg/dL, and
triglycerides ≥150 mg/dL. Because we did not measure
abdominal obesity, data refer only to a measure of overall
obesity (body mass index ≥30 kg/m2).
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Laboratory tests
Twenty-four–hour urine (protein excretion, elec-
trolytes, creatinine, ET-1), serum (electrolytes, creati-
nine, ET-1, renin, aldosterone, and lipid profiles), and
blood pressure were collected at baseline, and at 6 and
12 months. Twenty-four–hour urine samples for the de-
termination of proteinuria were provided by patients
carefully instructed in proper collection methods. Renal
function was determined by measuring creatinine clear-
ance by using 24-hour urine volume and urine and plasma
creatinine concentrations. All patients had creatinine
clearance greater than 50 mL/min/1.73 m2.
Plasma and urinary samples for ET-1 measurements
were collected and immediately centrifuges at 3000g for
10 minutes, and the plasmas were stored at −70◦C un-
til further analysis. ET-1 was measured by immunoas-
say (R&D Systems Inc., Minneapolis, MN, USA). The
detection limit was 1 pg/mL for ET-1. There was <1%
cross-reactivity with big endothelin 22-38. Intra-assay and
interassay coefficients of variation were 4.5% and 6.6%,
respectively. Results were expressed as pg/mL for plasma
and ng/g of urinary creatinine for urine.
Statistics
The continuous variables are expressed as mean ± SD.
Because proteinuria was not normally distributed, pro-
teinuria was analyzed after logarithmic transformation
for its skewed distribution. The transformation of the data
resulted in more normally distributed residuals. Base-
line characteristics and changes after drug intervention
between groups were compared by use of independent
samples t tests. Within-group changes were assessed by
paired Student t tests and repeated-measures analysis of
variance (ANOVA). The relationship between the de-
cline of proteinuria after the statin withdrawal and the
influencing factors such as patient age, gender, hyperten-
sion duration, lipid profiles, and statin use were evaluated
using linear and multiple regression analysis with SPSS
(version 10.0). Proteinuria was considered as a dependent
variable. For the categorical parameters, the differences
were compared by chi-square test and Fisher exact test if
case number <5. Statistical significance was inferred at a
two-tailed probability value of <0.05.
RESULTS
Baseline characteristics
A total of 134 patients met the criteria for inclusion,
and 52 of these patients (39%) met one or more crite-
ria for exclusion. There were a total of 82 evaluable pa-
tients (40 in the placebo group and 42 in the pravastatin
group). Table 1 presents the baseline and demographic
characteristics of patients in each group. Pravastatin was
very well tolerated by patients on statin therapy and none
had any significant subjective side effects. Patient compli-
ance with the treatment was >80% by pill count, which
was further confirmed by the significant effects on blood
lipids (Table 2). The number of antihypertensive agents
was similar in the two groups, with a mean number of
3.0 in the placebo group and 3.0 in the pravastatin group.
Forty-two patients on pravastatin received an average of
58 ± 24 mg/day losartan and 40 patients in the placebo
group of 59 ± 24 mg/day.
The first 6-month intervention program
There were no significant changes in blood pressure
after administering pravastatin (data not shown). We ob-
served no clinically meaningful changes in the parame-
ters indicative of renal function such as serum creatinine
and creatinine clearance throughout the study course
(Table 2).
Lipid profiles
The levels of total cholesterol, low-density lipoprotein
(LDL) cholesterol, HDL cholesterol, and triglycerides at
baseline and after 6 months are listed in Table 2. Com-
pared with the placebo group, pravastatin administration
caused significant reductions in plasma total and LDL
cholesterol levels, as well as increased HDL cholesterol
by 10%, 16%, and 8% (all P < 0.05), respectively.
Proteinuria and ET-1
Changes in urinary protein excretion are shown in
Table 2. The urinary protein excretion did not differ be-
tween the two groups at baseline. In pravastatin-treated
patients, proteinuria significantly reduced by 58% (from
1323 ± 592 mg/24 hours to 559 ± 251 mg/24 hours)
(P < 0.0001) compared with baseline values. As there
was a large standard deviation of proteinuria relative to
the mean, proteinuria amount was logarithmically trans-
formed to a normally distributed variable. In the sta-
tistical analysis of the transformed values, proteinuria
amount remained stable throughout the study in the
placebo group while it significantly reduced in patients
treated with pravastatin.
Urinary ET-1 levels were significantly reduced in
pravastatin-treated patients while plasma ET-1 levels re-
mained stable throughout the study.
The second 6-month withdrawal program
Baseline characteristics did not differ from statin-
treated patients who continued to receive statin ther-
apy or withdrawn statin therapy for the second 6-month
program. Blood pressure remained stable through the
second 6-month program between the two groups. How-
ever, total cholesterol concentrations were significantly
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Table 1. Baseline clinical characteristics of patients at a first 6 months of therapy
Parameters Placebo (N = 40) Pravastatin (N = 42) P value
Age years 48 ± 8 50 ± 9 NS
Gender M/F 27/13 29/13 NS
Blood pressure mm Hg
Systolic 124 ± 10 118 ± 10 NS
Diastolic 74 ± 5 72 ± 6 NS
Duration of hypertension years 13.6 ± 4.5 13.5 ± 5.2 NS
Body mass index kg/m2 24.6 ± 1.3 24.8 ± 1.4 NS
Cigarette smoking number (%) 26 (65) 25 (60) NS
Metabolic syndrome number (%) 21 (53) 23 (56) NS
Antihypertensive agents number (%)
b blocking agents 28 (70) 25 (60) NS
Calcium blocker 30 (75) 32 (76) NS
Diuretics 19 (48) 21 (50) NS
Data values are mean ± SD.
Table 2. Lipid profiles, renal function, and endothelin-1 (ET-1) at baseline and first 6-month intervention therapy
Placebo (N = 40) Pravastatin (N = 42)
Parameters Baseline Follow-up Baseline Follow-up
Cholesterol mg/dL
Total 202 ± 23 205 ± 27 208 ± 23 178 ± 20a
High-density lipoprotein 38 ± 5 38 ± 3 38 ± 5 41 ± 6a
Low-density lipoprotein 123 ± 25 116 ± 28 121 ± 24 102 ± 18a
Triglycerides mg/dL 237 ± 56 239 ± 56 249 ± 42 203 ± 40a
Dietary protein intake g/day 70 ± 11 68 ± 9 70 ± 11 71 ± 9
Creatinine clearance mL/min/1.73 m2 90 ± 19 94 ± 20 85 ± 16 98 ± 22
Plasma samples
Serum creatinine mg/dL 1.07 ± 0.18 1.05 ± 0.18 1.11 ± 0.19 1.13 ± 0.18
ET-1 pg/mL 1.84 ± 0.56 1.73 ± 0.57 1.87 ± 0.55 1.69 ± 0.50
Plasma renin activity ng/mL/hour 6.1 ± 2.9 6.0 ± 2.9 6.0 ± 2.4 5.9 ± 2.1
Aldosterone pg/mL 124 ± 42 113 ± 37 127 ± 39 118 ± 29
Urine samples
Protein excretion mg/24 hours 1207 ± 531 1262 ± 557 1323 ± 592 559 ± 251a
ET-1 ng/g urinary creatinine 29.9 ± 5.49 30.1 ± 6.9 28.6 ± 4.8 22.9 ± 4.5a
Data Values are mean ± SD.
aP < 0.05 compared with respective baseline data.
increased in withdrawal patients (181 ± 18 mg/dL for
continuing patients vs. 212 ± 22 mg/dL) (P= 0.002).
In those patients continuing pravastatin, protein-
uria remained stable further from 6 months to 1 year
(1328 ± 648 mg/24 hours at baseline, 613 ± 198 mg/24
hours at 6 months, and 629 ± 175 mg/24 hours at 1 year).
After crossover to placebo, by contrast, the pravastatin-
treated patients lost 97% of the proteinuria reduction that
had been realized with therapy. Proteinuria returned to-
ward baseline (1247 ± 600 mg/24 hours at baseline, 499 ±
289 mg/24 hours at 6 months, and 1231 ± 459 mg/24 hours
at 1 year) (P= 0.4 compared with proteinuria at baseline
and P< 0.0001 compared with proteinuria at 1 year in
patients continuing pravastatin) (Figs. 2 and 3). Urinary
excretion of ET-1 increased 27% after withdrawing
statins compared with that at the time of using statins.
Correlation
To identify determinants of decrease in urinary protein
excretion, multivariate analysis was performed for pa-
tients who were treated with statins for at least 6 months
(N = 36) (Table 3). Multivariate regression analysis with
log proteinuria as dependent variable and age, gender,
hypertension duration, changes in hemodynamics, lipid
profiles, and the presence or absence of pravastatin as
independent variables was performed to investigate the
effect of pravastatin and other risk factors on proteinuria.
The continued use of statin was a factor which was signif-
icantly related to long-term improvement in proteinuria
(b = −0.814, P= 0.001, R2 = 0.696).
The linear regression models in the initial statin-treated
group showed that changes in urinary ET-1 correlated
with urinary protein excretion (change in log proteinuria
(%) = 0.35 ∗ change in urinary ET-1 (%) + 3.55) (r =
0.83, P < 0.0001) (Fig. 4). Changes in LDL cholesterol,
HDL cholesterol, or triglycerides were not a predictor of
change in log urinary protein excretion. These data in-
dicate the nonlipid effect of pravastatin on proteinuria.
Additionally, no significant correlation was observed be-
tween changes in proteinuria and hemodynamics (sys-
tolic, diastolic, and mean blood pressure).
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Fig. 2. Proteinuria for each treatment group as a function of time. Pa-
tients were randomized 10 mg of pravastatin (•) (N = 42) or placebo (◦)
(N = 40) at baseline. Initial pravastatin-treated patients were random-
ized to continue () (N = 19) or withdraw () (N = 17) pravastatin. Pro-
teinuria significantly reduced in pravastatin-treated group compared
with placebo at 6 months. In those patients continuing pravastatin, pro-
teinuria remained stable further from 6 months to 12 months. However,
the benefit was abrogated after the drug is discontinued. ∗P < 0.0001
compared with baseline; †P< 0.0001 compared with data at 6 months;
‡P= 0.0005 compared with the withdrawal group at 12 months.
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Fig. 3. The bars indicate the percent change in 24-hour urine pro-
tein excretion (, UPE) in patients treated with placebo ( N = 40
at 6 months, N = 35 at 12 months), pravastatin for 6 months but sub-
sequent discontinuing for 6 months ( ) (N = 17), and pravastatin for
12 months () (N = 19). ∗P < 0.0001 compared with respective base-
line; †P< 0.0001 compared with data at 6 months.
DISCUSSION
Our results have demonstrated for the first time that
the combination of ARBs and statins may provide a
new therapeutic approach to optimal renoprotection and
pravastatin for improving proteinuria loses the benefit of
therapy after discontinuing the drug in patients with well-
controlled hypertension independently of lipid profiles.
Our conclusions are supported by three lines of ev-
idence. First, pravastatin further improved proteinuria
in patients already treated with ARBs, suggesting that
statins may play a role in the pathogenesis of attenu-
ating proteinuria in an angiotensin-independent man-
ner. There were no previous studies concerning the
effect of statins in additional to ARBs on proteinuria in
well-controlled hypertensive patients without hyperlipi-
demia. Full remission of proteinuria is seldom obtained
by administering ARBs alone, particularly when therapy
is started late [12]. Multidrug intervention has been pro-
posed. The addition of pravastatin on the background
of ARBs led to a further striking reduction of protein-
uria even at the late phase of hypertension with a mean
duration of 13 12 years. Our results were compatible with
the notion that the combination of ARB and statin pro-
vide a way to maximize antiproteinuric effect by different
mechanisms versus monotherapy [6].
Second, renoprotection was abrogated rather than an
increase in damage compared with placebo group after
withdrawal of statin treatment. Patients continuing on
pravastatin had no change in proteinuria. Proteinuria im-
provement decline after statin therapy is stopped suggests
that the improvement with pravastatin treatment was due
to the drug’s action.
Finally, because of its significant correlation of the
changes between proteinuria and urinary ET-1 levels, it
is likely that the involved mechanism could be related to
inhibit renal ET-1 synthesis by pravastatin.
Mechanisms
The mechanisms by which pravastatin added on top of
ARBs affects the proteinuria remain undefined. How-
ever, several factors can be excluded. First, hemody-
namics were not affected. Systolic and diastolic blood
pressures were similar in the two groups at baseline and
during follow-up, weakening the role of hemodynam-
ics in the superior protective effects of the combination
therapy. Glorioso et al [13] have shown hemodynamic
improvement after 16-week therapy with pravastatin in
hypertensive patients, which was not consistent with
our stable hemodynamics throughout the study in
pravastatin-treated patients. The discrepancy could be
due to differences in protocols, patient population, and
periods of treatment. In fact, statins have been shown
to decrease elevated but not normal blood pressure [14].
Our results were consistent with the findings of Bianchi et
al [15], showing that blood pressure was not significantly
different between well-controlled hypertensive patients
treated with or without statin.
Second, lipid profiles were also not affected. Abnor-
malities of lipid metabolism are extremely common in a
variety of renal diseases, which promote the acceleration
of renal damage [16]. Correction of hyperlipidemia may
ameliorate renal injury. However, our results showed a
poor correlation between the changes of lipid profiles and
proteinuria, suggesting that other nonlipid factors may be
important in causing proteinuria regression. This result
was compatible with previous findings of Park et al [17],
showing that statins improve renal function independent
of cholesterol changes.
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Table 3. Multivariate analysis of independent factors for worsening proteinuria during statin withdrawal (model R2 = 0.696)
Factor Standardized b coefficient 95% CI P value
Treatment assignment [statin (+) vs. (−)] −0.814 −0.724 to −0.215 0.001
Hypertension duration (per additional year) 0.345 0.001 to 0.006 0.01
Gender (male vs. female) 0.061 −0.106 to 0.177 0.61
Age (per additional year) −0.046 −0.01 to 0.007 0.71
Systolic blood pressure (per additional mm Hg) −0.037 −0.012 to 0.010 0.87
Mean blood pressure (per additional mm Hg) 0.029 −0.016 to 0.018 0.90
High-density lipoprotein cholesterol (per additional mg/dL) −0.036 −0.021 to 0.015 0.77
Low-density lipoprotein cholesterol (per additional mg/dL) −0.040 −0.005 to 0.004 0.83
Triglycerides (per additional mg/dL) −0.226 −0.003 to 0.001 0.15
y = 0.35x + 3.55
Withdrawal group (N = 17)
Continuing group (N = 19)
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Fig. 4. Correlation of the change (%) be-
tween log proteinuria and urinary endothelin-
1 in the initial pravastatin-treated patients
(r = 0.83, P < 0.0001, N = 36). A greater in-
crease of urinary endothelin-1 release was
associated with a greater worsening of pro-
teinuria. UPE is urine protein excretion.
It is well established that when proteinuria ensues, a
variety of mechanisms comes into play that perpetuate
and contribute to the progression. Among those, ET-1
has received a great of attention [18]. In this study, al-
though pravastatin did not reduce plasma ET-1 levels,
renal ET-1 production assessed by urinary ET-1 excre-
tion was significantly declined, implying the importance
of local renal ET-1 effects of pravastatin. Urinary ET-1
and plasma ET-1 are two distinct functional systems, each
of which is regulated by its own control mechanisms. Be-
cause plasma ET-1 is produced by a great variety of nor-
mal cell types including endothelial cells, neurons, guts,
and renal cells, plasma ET-1 levels may be affected in
renal or nonrenal diseases. However, urinary ET-1 ap-
pears to be mainly derived from the amount of ET-1
locally produced in the kidney [19]. Thus, although ET-
1 is removed by the kidney, it has been suggested that
urinary ET-1 reflects its renal synthesis rather than its
removal from the circulation. Pravastatin can be selec-
tively taken up by the kidney [20]. It is not surprising
that renal ET-1 synthesis can be inhibited by pravastatin
administration.
It appears from our study that the attenuated protein-
uria is related to a cholesterol-independent decreased re-
nal ET-1 level in response to statin treatment. The finding
was further supported by the significant correlation be-
tween worsening proteinuria and urine ET-1 levels during
the period of withdrawal, implying the damaging effects
of proteinuria may be caused by stimulation of renal ET-1
production. Statins have profound effects of cellular sig-
naling, which are a consequence of the statin-mediated
inhibition of Rho-GTPase by preventing their anchoring
in the plasma membrane [21]. Regulation of Rho activity
by statins is separate from that of statins on lipids. Inhibi-
tion of Rho signaling by statins can activate peroxisome
proliferator-activated receptors [22], which in turn sup-
press ET-1 secretion [23]. Besides, decreases in regional
ET-1 concentrations may result from decreases in ET-
1 production. Because ET-1 is not stored intracellularly
but is generated de novo and its production is controlled
at the level of mRNA production [24], we have demon-
strated that pravastatin inhibits expression of preproET-1
mRNA [25]. Taken together, either reduced secretion or
synthesis of ET-1 after administering pravastatin reduced
renal ET-1 levels.
Pravastatin further improved proteinuria in patients
treated with losartan, suggesting that pravastatin may
play a role in the pathogenesis of attenuating protein-
uria in an angiotensin-independent manner. The mech-
anisms by which pravastatin provides additional effect
on proteinuria remain unclear. However, it is unlikely by
inhibition of pravastatin-induced angiotensin II activity.
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The average dose of losartan used was >50 mg/day, which
was shown to have maximal inhibition of angiotensin II
activity in humans [26]. Thus, although statins have been
proven to inhibit the effect of angiotensin II on organ in-
jury, it is unlikely that pravastatin administration reduces
the amount of proteinuria by more complete blockade of
the renin-angiotensin system. Furthermore, the inhibi-
tion of angiotensin II attenuates proteinuria is mediated
by increasing plasma renin activity and/or aldosterone
concentrations [27], which were not observed in our pa-
tients administered with pravastatin. The observation was
consistent with the notion that pravastatin can affect bio-
logic activity in an angiotensin stimulation–independent
manner [28].
Little is known about the effects of statin withdrawal
on proteinuria. To understand the mechanism underlying
the worsening proteinuria after statin withdrawal, uri-
nary ET-1 levels were determined. Consistent with the
present study, protection of cerebral ischemia was rapidly
abrogated 2 days following withdrawal of statins [29].
Withdrawing statin treatment restored the availability of
isoprenoids and resulted in a massive membrane translo-
cation and overshoot-activation of Rho [9], causing up-
regulation of renal ET-1 production [23]. Our results were
not consistent with previous studies, showing a rebound
phenomenon after the withdrawal of stain therapy [10].
The up-regulation of urinary ET-1 concentrations sim-
ilar to pretreatment levels after withdrawal treatment
was not consistent with a rebound mechanism. The ex-
planation for the discrepancy remains elusive. However,
long-lasting pleiotropic effects of statins other than ET-1
down-regulation may partly compensate for modulation
of proteinuria such as nitric oxide, a determinant factor
of proteinuria [30], and attenuate the adverse effects of
statin withdrawal.
Clinical implications
Our findings may be of clinical relevance because the
random assignment to treatment groups and the use
of a double-blind and placebo-controlled design mini-
mized the potential for bias. All of previous studies were
performed in patients with either untreated hyperten-
sion or after antihypertensive agents were washed out.
Because an antihypertensive washout period was be-
lieved to be unethical, the study including medicated pa-
tients reflects a clinical practical setting. Second, clinicians
may consider as a drug holiday if uncertain about the
benefit of continuing medications. There is compelling
evidence that withdrawal of statin medication impairs
vascular function and negatively affects outcomes [10].
Our study shows that withdrawal of pravastatin ther-
apy worsened the proteinuria severity of patients who
had initially benefited from this treatment. Proteinuric
patients who respond to pravastatin therapy may re-
quire chronic treatment to maintain improvements in
proteinuria. Furthermore, previous studies have shown
that the level of proteinuria after medication withdrawal
and the changes in proteinuria had a positive relation-
ship with the decline of renal function [31]. Thus, with-
drawal of statin therapy in proteinuric patients should be
avoided.
Study limitations
There were several limitations of this study. First, al-
though pravastatin significantly reduces the severity of
proteinuria, it did not affect creatinine clearance com-
pared with baseline. The finding was not consistent with
the notion that a greater proteinuria is associated with
a faster renal function decline [1] and that reduction in
urinary proteins is associated with a subsequent benefi-
cial effect on the progression of renal disease [1]. It is
likely that the observation time of 12 months was too
short to demonstrate significant differences of creatinine
clearance. Recently, statin treatment has been shown to
prevent decline of renal function over a period of 3 years
[32].
A potential problem with the present study is whether
pravastatin attenuates proteinuria by directly inhibiting
renal ET-1 synthesis. Although significant correlation was
observed between proteinuria and ET-1 levels, we can not
definitely confirm the cause-effect relationship in the ab-
sence of administering endothelin receptor blockers. We
can not rule out the possibility that increased urinary ET-
1 levels only reflected increased excretion of proteinuria.
It appears possible that the withdrawal of statin therapy
was related to the worse clinical course of these patients
who might not have allowed continuing statin therapy.
However, in a multivariate analysis, including patients
who were treated with statins for at least 6 months and
adjusting for all baseline characteristics (Table 3), the dif-
ference in proteinuria between patients who continued
to receive statins and those with discontinued statin ther-
apy remained robust [−0.814 (95% CI −0.724 to –0.215)]
(P= 0.001).
Although this study has demonstrated that 6 months
of pravastatin therapy is inadequate for preventing recur-
rence of proteinuria in hypertensive patients, how much
longer these patients should be treated and how to with-
draw the drug are not known. Prolongation of pravastatin
may only delay recurrences until pravastatin is stopped
and does not reduce the risk of proteinuric recurrence.
It seems, therefore, that an important clinical goal is to
evaluate patients according to individual and persistent
risk of recurrence and to identify those who may or may
not need prolonged pravastatin.
We did not have renal biopsy data. Different re-
nal pathology may follow different disease progression
[33]. To avoid the confounding factors, patients with
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hyperlipidemia and diabetes mellitus were excluded from
this study, using a homogenous group of normolipi-
demic patients with well-controlled essential hyperten-
sion. However, because of none of these patients under-
went renal biopsy, we can not exclude the possibility of
some of these patients may have renal diseases other than
hypertensive nephrosclerosis, a most common pathologic
finding in essential hypertension patients [34]. Further-
more, it remains unclear whether the transient improve-
ment of statin-related proteinuria is associated with renal
structural changes.
CONCLUSION
The present study demonstrates that pravastatin ad-
ministration in additional to ARBs was associated with
further reduction of urinary protein excretion probably
mediated by reducing renal ET-1 production in patients
with well-controlled hypertension, independent of blood
pressure and lipid changes. Withdrawal of pravastatin
treatment leads to an abrogation of statin-mediated reno-
protection. The mechanism relates to a rebound effect on
renal ET-1 levels. Although we did not observe impair-
ment in renal function, withdrawal of statin treatment in
proteinuric patients may impair their outcome and there-
fore should be avoided. More clinical studies are needed
to characterize the time course and significance of the
clinical events after the withdrawal of statin therapy and
their correlation with the up-regulation of renal ET-1 syn-
thesis.
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